Xtant Medical Announces U.S. Commercial Launch of the Matriform® Si for Spinal Fusion Procedures
August 24 2020 - 08:30AM
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global
medical technology company focused on surgical solutions for the
treatment of spinal disorders, today announced the U.S. commercial
launch of the Matriform® Si, a silicated synthetic bone graft strip
designed and cleared for spinal fusion procedures. The
Matriform Si Strip is resorbable, osteoconductive, and has a
cancellous bone-like structure. It is prepared from
Beta-tricalcium phosphate (β-TCP) and porcine collagen for its
intended use in filling and bridging degenerative or traumatic bone
defects.
“We are excited to launch Matriform Si in the
U.S., which expands our biologics portfolio offering and increases
our footprint in the U.S. orthopedic Bone Graft Substitute market,”
said Kevin Brandt, Chief Commercial Officer of Xtant Medical. “This
innovative synthetic is an ultraporous, interconnected structure
that is designed to enhance new bone formation and mechanical
stability while preventing premature dissolution for spinal fusion
procedures. Our team remains committed to advancing our product
portfolio, supporting distributors, and providing new tools for
surgeons to drive better patient care. Bringing the Matriform
Si to market is a testament to our team’s focus and
dedication.”
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/5d59db94-c877-4c1e-a75c-a31465e45437
Matriform® Si was developed to resemble the
composition and porous structure of natural human bone. Comprised
of 96% pure phase β-TCP granules and 4% bioglass, Matriform Si is
designed to provide the ideal biomimetic scaffold for spinal fusion
procedures. The flexible strip is designed to offer excellent
handling and shape memory, ensuring direct contact with the surface
of healthy bone.
Physicians and surgeons interested in learning
more about the Matriform Si and other Xtant Medical products can
contact Marketing@xtantmedical.com.
About Xtant Medical Holdings,
Inc.
Xtant Medical Holdings, Inc.
(www.xtantmedical.com) is a global medical technology company
focused on the design, development, and commercialization of a
comprehensive portfolio of orthobiologics and spinal implant
systems to facilitate spinal fusion in complex spine, deformity and
degenerative procedures. Xtant people are dedicated and talented,
operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and
registered trademarks of Xtant Medical Holdings, Inc. or its
affiliates, registered as indicated in the United States, and other
countries. All other trademarks and trade names referred to in this
release are the property of their respective owners.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
that are predictive in nature, that depend upon or refer to future
events or conditions, or that include words such as “expects,”
“anticipates,” “intends,” “plans,” “believes,” “continue,”
“future,” “will,” “may,” “continue,” similar expressions or the
negative thereof, and the use of future dates. The Company cautions
that its forward-looking statements by their nature involve risks
and uncertainties, and actual results may differ materially
depending on a variety of important factors, including, among
others: risk involved in the introduction of new products; the
effect of the COVID-19 pandemic on the Company’s business,
operating results and financial condition; the Company’s future
operating results and financial performance; the ability to
increase or maintain revenue; the ability to remain competitive;
the ability to innovate and develop new products; the effect of
management changes and the ability to engage and retain qualified
personnel; government and third-party coverage and reimbursement
for Company products; the ability to obtain and maintain regulatory
approvals and comply with government regulations; the effect of
product liability claims and other litigation to which the Company
may be subject; the effect of product recalls and defects; the
ability to obtain and protect Company intellectual property and
proprietary rights and operate without infringing the rights of
others; the ability to complete its pending debt restructuring,
service its debt, comply with its debt covenants and access
additional indebtedness; the ability to obtain additional financing
and other factors. Additional risk factors are contained in the
Company’s Annual Report on Form 10-K for the year ended December
31, 2019 filed with the SEC on March 5, 2020, as supplemented by
subsequent disclosures in the Company’s Quarterly Report on Form
10-Q for the quarterly period ended June 30, 2020 and in future
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
Investors are encouraged to read the Company’s filings with the
SEC, available at www.sec.gov, for a discussion of these and other
risks and uncertainties. The Company undertakes no obligation to
release publicly any revisions to any forward-looking statements to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events, except as required by law.
All forward-looking statements attributable to the Company or
persons acting on its behalf are expressly qualified in their
entirety by this cautionary statement.
Investor Relations Contact
David CareyLazar FINNPh: 212-867-1762Email:
david.carey@finnpartners.com
Xtant Medical (AMEX:XTNT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Xtant Medical (AMEX:XTNT)
Historical Stock Chart
From Mar 2023 to Mar 2024